2025年四季度公募基金成绩单已出炉，"医药女神" 葛兰又一次站在了风口上。 葛兰能成为千亿顶流，一半是实力加持，一半是踩中了行业风口。 而中欧基金则借着她的东风，快速坐稳了主动权益赛道的头部位置，两人的崛起是一场互相成就。 事实上，和其他基金经理比，葛兰的专业底色足够硬。 她是国内医疗主题基金里少有的美国生物医学工程博士，懂医药研发、懂行业逻辑，这也是她能精准抓 住医药赛道机遇的关键。 数据显示，截至2025年年末，葛兰手里管的基金总规模缩减到了353.89亿元，比三季度少了81.55亿元； 而距离2021年千亿巅峰，已跌去750亿元，缩水幅度达68%。 此前，葛兰凭着年化超30%的收益封神，一举成为中欧基金顶流，被基民广泛熟知；如今，随着业绩持 续回调、规模不断缩水，质疑声越来越多。 当顶流的光环褪去，靠明星基金经理撑起的公募巨头，该怎么跳出 "一人衰、公司忧" 的怪圈？这不仅 是中欧的难题，更是整个公募行业都要面对的考验。 基金规模缩水近七成 2016到2021年，是葛兰的黄金五年，也是中欧基金借势起飞的五年。 那时候医药板块迎来牛市，尤其是创新药、医药研发生产外包（CXO）赛道，涨得一飞冲天，葛兰的 ...

Core Viewpoint - The report highlights the performance of the China Europe Medical Health Mixed Fund managed by Ge Lan and Zhao Lei, indicating a decline in total fund size and negative returns compared to benchmarks [1][4]. Fund Performance - As of December 31, 2025, the total size of the funds managed by Ge Lan decreased from 43.544 billion to 35.389 billion yuan [1]. - The A-class share of the China Europe Medical Health Mixed Fund recorded a net value growth rate of -14.81%, while the C-class share saw a decline of -14.98%, both underperforming the benchmark return of -8.21% [1][3]. Holdings Overview - The top ten holdings of the China Europe Medical Health Fund include WuXi AppTec, Heng Rui Medicine, and Kanglong Chemical, with notable increases in holdings for Hai Si Ke and Tai Ge Medicine, while reductions were seen in stocks like Ke Lun Pharmaceutical and Xin Li Tai [1][2]. Market Context - In Q4 2025, the CSI Pharmaceutical Index fell by 12.7%, underperforming the CSI 300 Index, which declined by only 0.2%. The report notes significant differentiation within sub-sectors, with innovative industries experiencing corrections while traditional Chinese medicine and pharmaceutical commerce remained relatively stable [3]. Future Outlook - Looking ahead to Q1 2026, improvements in global liquidity are expected to boost investment and financing in innovative pharmaceuticals, supported by domestic policy enhancements. The innovative drug and device industry is anticipated to maintain a high level of activity, with several key domestic drugs approaching critical data readouts [4][5]. - The report suggests that the pharmaceutical sector may continue to experience structural trends due to macroeconomic improvements, supportive industry policies, and ongoing innovation, with investment opportunities focusing on the progress of innovative drug and device exports, domestic substitution in equipment, and recovery in consumer healthcare demand [5].

Group 1 - Multiple high-performing funds have recently reduced their subscription limits, indicating a new wave of "purchase restrictions" aimed at managing inflows and protecting existing investors' interests [1][2] - For example, funds managed by Lan Xiaokang, including China Europe Dividend Enjoyment A, have lowered their daily subscription limit to 10,000 yuan, following previous reductions from 1 million yuan to 500,000 yuan [1] - The strong performance of these funds, with year-to-date returns of 42.93%, 32.18%, and 45.79%, has attracted significant investor interest, prompting fund companies to balance scale management with investment stability [1] Group 2 - The trend of imposing purchase limits is not isolated, as other funds like Guangfa Carbon Neutrality and E Fund Kexiang have also suspended large subscriptions due to their impressive year-to-date returns of 65.03% and 61.49%, respectively [2] - In the QDII sector, Guangfa Global Select has set a subscription limit of 10,000 yuan for institutional investors, reflecting a broader trend of limiting large inflows in high-performing products [2] - This phenomenon highlights a shift in the public fund industry towards prioritizing refined operations over mere scale expansion, as evidenced by multiple funds implementing purchase restrictions [3] Group 3 - The recent wave of purchase restrictions reflects several industry trends, including the tendency for high-performing funds to attract significant capital, which can pressure fund managers' strategies and increase costs [3] - Fund managers are seeking to control the pace of capital inflows to avoid forced adjustments in their portfolios due to sudden surges in subscriptions [3] - This shift indicates a transition in the public fund industry from a focus on scale-driven growth to a more quality-oriented approach centered on risk control, investment discipline, and long-term returns [3]

Core Viewpoint - The recent trend of performance-driven funds implementing purchase limits is primarily aimed at controlling fund size to maintain the effectiveness of investment strategies, reflecting a cautious approach to managing potential market risks and ensuring stable growth for investors [2][10]. Group 1: Fund Purchase Limits - On November 22, China Europe Fund announced that starting November 24, the daily purchase limit for four funds managed by Lan Xiaokang will be reduced to 500,000 yuan [4]. - This year, over 230 active equity funds have announced the suspension of large purchases or general purchases, with many of these funds showing strong performance and reaching new net asset value highs [10]. - The recent limits on fund purchases are a response to the significant structural characteristics observed in the A-share market, which have led to concentrated investor interest in high-performing funds [10]. Group 2: Fund Performance - As of November 20, the one-year performance of several funds managed by Lan Xiaokang, including China Europe Dividend Enjoyment A and China Europe Value Return A, showed returns of 38.93%, 30.24%, and 41.68%, all exceeding their performance benchmarks [6]. - Other high-performing funds, such as China Europe Small Cap Growth A and China Europe Digital Economy A, reported one-year returns of 57.39% and 126.55%, respectively, placing them among the top tier of similar funds [7]. - The trend of limiting purchases among high-performing funds indicates a cautious stance from fund managers regarding the potential for market overheating and valuation bubbles in specific sectors [10]. Group 3: Investment Strategy Insights - Lan Xiaokang emphasizes the need to adjust investment strategies in light of global changes, advocating for a balanced allocation between precious metals and quality Chinese assets over the next 3 to 10 years [6]. - The cautious approach to fund management reflects a broader industry trend where fund managers are increasingly focused on the stability of net asset values and the long-term profitability of their investors [10].

Core Insights - The recent surge in the private placement market has attracted significant attention, particularly with prominent fund managers participating in the Baili Tianheng private placement [1] - On September 23, China Europe Fund announced that its funds managed by Ge Lan, including China Europe Medical Health and China Europe Medical Innovation, participated in the private placement of Baili Tianheng [1] - This private placement not only highlights the focus on pharmaceutical-themed funds but also indicates that public funds remain actively engaged in seizing structural opportunities despite fluctuations in the pharmaceutical sector [1] Group 1 - The Baili Tianheng private placement has become a prominent platform for pharmaceutical funds to showcase their strategies [1] - The participation of both long-term pharmaceutical-focused funds and comprehensive growth strategy products reflects a strong enthusiasm for allocation in this private placement [1] - The event leaves room for further market performance expectations, suggesting potential future opportunities in the sector [1]

Group 1 - The core point of the article is that Yongying Fund has implemented a purchase limit of 10,000 yuan per day for individual fund accounts of Yongying Technology Smart Selection starting from September 5, 2023, to protect the interests of fund shareholders [1][3] - Yongying Technology Smart Selection has achieved a year-to-date return of 177.8%, ranking first among all funds in the market as of September 3, 2023 [2][3] - The fund's total assets reached 1.166 billion yuan by the end of the second quarter of 2025, with a cumulative increase of 215.03% since its establishment in October 2024 [3] Group 2 - The recent surge in the fund's performance, with a monthly increase of over 47%, has led to increased investor interest, prompting the fund to further tighten purchase limits from 1 million yuan to 10,000 yuan within a week [5] - The fund management emphasizes the importance of rational decision-making among investors, aiming to avoid impulsive large investments due to market emotions and to maintain the stability and effectiveness of investment strategies [3][6] - The industry is witnessing a trend where over a hundred funds have announced purchase limits since August, indicating a shift from scale-oriented strategies to investor return-oriented strategies [2][10]

Core Viewpoint - The article discusses the recent decision by Yongying Fund to impose purchase limits on its top-performing fund, Yongying Technology Smart Selection, which has seen a year-to-date return of 177.8%, the highest in the market. This move is aimed at protecting existing investors and maintaining the fund's investment strategy effectiveness [2][3][9]. Group 1: Fund Performance and Limits - Yongying Technology Smart Selection has achieved a return of 177.8% year-to-date, making it the top fund in the market as of September 3 [2][3]. - The fund's total assets reached 1.166 billion RMB by the end of Q2 2025, with a total increase of 215.03% since its inception in October 2024 [3]. - Starting September 5, the fund will limit individual account purchases to 10,000 RMB per day, following a previous limit of 1 million RMB announced on August 27 [3][5]. Group 2: Reasons for Purchase Limits - The imposition of purchase limits is intended to guide investors towards rational decision-making and to prevent impulsive large investments due to market emotions [3][9]. - The limits also aim to control the growth of the fund's size, ensuring the stability and effectiveness of its investment strategy, thereby securing long-term sustainable returns for investors [3][9]. - The trend of limiting purchases is observed across over a hundred funds since August, indicating a shift in the industry from a scale-oriented approach to one focused on investor returns [2][8][9]. Group 3: Market Context and Future Outlook - The article notes a recent market recovery, which has led to increased interest in high-performing funds, prompting many fund managers to implement purchase limits [2][8]. - The fund management emphasizes the importance of understanding the underlying assets and risks associated with investments, advocating for a cautious approach to investment decisions [6][7]. - Looking ahead, the fund will focus on global cutting-edge models and emerging applications, particularly in the cloud computing industry, to identify investment opportunities [6].

Group 1 - The core viewpoint of the articles highlights the increasing trend of fund subscription limits, particularly for the Yongying Technology Smart Fund, which has implemented a daily purchase limit of 10,000 yuan per account starting September 5, following a previous limit of 1 million yuan [1][2][3] - The Yongying Fund's decision to impose these limits is driven by two main considerations: to guide investors towards rational decision-making and to control the growth of the fund's scale, ensuring the stability and effectiveness of investment strategies for sustainable long-term returns [1][2] - As of September 3, the Yongying Technology Smart Fund has achieved an impressive performance of over 177% year-to-date, making it a leader among all funds, with a significant net asset value increase of over 46% in the past month [2][3] Group 2 - The articles indicate a broader trend in the industry, with over a hundred funds implementing subscription limits in August, as the market began to recover, reflecting a renewed "subscription limit wave" among high-performing funds [3][4] - Various funds, including those managed by Manulife and Huatai-PB, have also announced subscription limits, with some as low as 10,000 yuan, aimed at controlling fund size and protecting existing investors from potential losses due to market volatility [4][5] - The rationale behind these subscription limits is to maintain the effectiveness of investment strategies and to prevent the dilution of fund returns that can occur when new capital enters at high net asset values [5]

Group 1 - The core viewpoint of the article is that the "champion funds" are implementing stricter purchase limits to manage fund size and protect investor interests [2][3][5] - Yongying Technology Smart Selection Fund has set a daily purchase limit of 10,000 yuan per account starting September 5, after previously allowing a limit of 1 million yuan [2][3] - The fund's performance has been outstanding, with a year-to-date return exceeding 177%, making it a leader among all funds [5][6] Group 2 - The fund management emphasizes the importance of rational decision-making among investors to avoid impulsive large investments due to market emotions [2][6] - The recent trend of fund purchase limits is seen across the industry, with over a hundred funds implementing similar restrictions in August to control fund size and maintain investment strategy effectiveness [6][7] - The limits are also intended to protect existing investors from potential losses due to market volatility when new funds enter at high valuations [7]

Core Viewpoint - The article discusses the recent increase in purchase limits for the "Champion Fund," specifically the Yongying Technology Select Fund, aimed at protecting investors and maintaining investment strategy effectiveness [2][4][6]. Group 1: Fund Purchase Limits - On September 4, Yongying Fund announced a new purchase limit of 10,000 yuan per day per account for the Yongying Technology Select Fund, effective from September 5 [4][6]. - This follows a previous limit of 1 million yuan per day per account that was set just a week earlier [2][6]. - The fund management cites two main reasons for these limits: to guide investors towards rational decision-making and to control the growth of the fund's scale [2][6]. Group 2: Fund Performance and Strategy - As of September 3, the Yongying Technology Select Fund has achieved a performance of over 177% year-to-date, making it a leader among all funds [6]. - The fund, established in late October 2024, capitalized on opportunities in the cloud computing market, with a net asset value increase of over 46% in the past month [6]. - The fund's strategy for the second half of the year includes focusing on global cutting-edge models, emerging applications, and the operational status of key companies in the cloud computing sector [6]. Group 3: Industry Trends - The article notes a broader trend of purchase limits being implemented across over a hundred funds in August, as the market began to recover [8]. - Various funds, including those managed by Manulife and Huatai-PB, have set limits as low as 10,000 yuan to manage fund size and protect existing investors [8]. - Industry insiders suggest that these limits are necessary to maintain investment strategy effectiveness and to prevent new investors from entering at high market levels, which could lead to losses [8].